Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III - The OVAR-IMRT-02 Study

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Rochet, Nathalie ^a   Kieser, Meinhard ^a   Sterzing, Florian ^a   Krause, Sonja ^a   Lindel, Katja ^a   Harms, Wolfgang ^a   Eichbaum, Michael H ^a   Schneeweiss, Andreas ^a   Sohn, Christof ^a   Debus, Juergen ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMEN; ABDOMINAL RADIOTHERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LIVER; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PELVIS; PERITONEAL CAVITY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIATION DOSE DISTRIBUTION; TREATMENT DURATION; ADJUVANT THERAPY; ADULT; AGED; CARCINOMA; CLINICAL TRIAL; DISEASE COURSE; FEASIBILITY STUDY; FOLLOW UP; METHODOLOGY; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; RADIATION EXPOSURE; REMISSION;

ANTINEOPLASTIC AGENT;

ABDOMEN; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DISEASE PROGRESSION; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, INTENSITY-MODULATED; REMISSION INDUCTION;

EID: 79251559091     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-41     Document Type: Article

References (35)

1. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002, 20:1248-1259. 10.1200/JCO.20.5.1248, 11870167.
2. Cannistra SA, Bast RC, Berek JS, Bookman MA, Crum CP, DePriest PD, et al. Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol 2003, 21:129s-132s. 10.1200/JCO.2003.04.003, 12743127.
3. Lambert HE, Gregory WM, Nelstrop AE, Rustin GJ. Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population. Int J Gynecol Cancer 2004, 14:772-778. 10.1111/j.1048-891X.2004.014507.x, 15361183.
4. McGuire WP. Current status of taxane and platinum-based chemotherapy in ovarian cancer. J Clin Oncol 2003, 21:133s-135s. 10.1200/JCO.2003.01.066, 12743128.
5. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21:3194-3200. 10.1200/JCO.2003.02.153, 12860964.
6. Donato ML, Aleman A, Champlin RE, Saliba RM, Wharton JT, Burke TW, et al. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 2004, 33:1219-1224. 10.1038/sj.bmt.1704473, 15122311.
7. Dufour P, Bergerat JP, Barats JC, Giron C, Duclos B, Dellenbach P, et al. Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. Cancer 1994, 73:1865-1869. 10.1002/1097-0142(19940401)73:7<1865::AID-CNCR2820730715>3.0.CO;2-T, 8137212.
8. Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD, et al. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2003, 21:2849-2855. 10.1200/JCO.2003.11.018, 12885800.
9. Dembo AJ. Abdominopelvic radiotherapy in ovarian cancer. A 10-year experience. Cancer 1985, 55:2285-2290. 10.1002/1097-0142(19850501)55:9+<2285::AID-CNCR2820551436>3.0.CO;2-4, 3919934.
10. Dembo AJ. Epithelial ovarian cancer: the role of radiotherapy. Int J Radiat Oncol Biol Phys 1992, 22:835-845. 10.1016/0360-3016(92)90777-F, 1555974.
11. Smith JP, Rutledge FN, Delclos L. Postoperative treatment of early cancer of the ovary: a random trial between postoperative irradiation and chemotherapy. Natl Cancer Inst Monogr 1975, 42:149-153.
12. Kapp KS, Kapp DS, Poschauko J, Stucklschweiger GF, Hackl A, Pickel H, et al. The prognostic significance of peritoneal seeding and size of postsurgical residual in patients with stage III epithelial ovarian cancer treated with surgery, chemotherapy, and high-dose radiotherapy. Gynecol Oncol 1999, 74:400-407. 10.1006/gyno.1999.5477, 10479500.
13. Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann Oncol 1997, 8:327-333. 10.1023/A:1008256431090, 9209661.
14. MacGibbon A, Bucci J, MacLeod C, Solomon J, Dalrymple C, Firth I, et al. Whole abdominal radiotherapy following second-look laparotomy for ovarian carcinoma. Gynecol Oncol 1999, 75:62-67. 10.1006/gyno.1999.5541, 10502427.
15. Pickel H, Lahousen M, Petru E, Stettner H, Hackl A, Kapp K, et al. Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer. Gynecol Oncol 1999, 72:215-219. 10.1006/gyno.1998.5184, 10021304.
16. Thomas GM. Is there a role for consolidation or salvage radiotherapy after chemotherapy in advanced epithelial ovarian cancer?. Gynecol Oncol 1993, 51:97-103. 10.1006/gyno.1993.1253, 8244182.
17. Thomas GM, Dembo AJ. Integrating radiation therapy into the management of ovarian cancer. Cancer 1993, 71:1710-1718. 10.1002/1097-0142(19930315)71:6<1977::AID-CNCR2820710609>3.0.CO;2-D, 8431909.
18. Sorbe B. Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer 2003, 13:278-286. 10.1046/j.1525-1438.2003.13193.x, 12801256.
19. Einhorn N, Lundell M, Nilsson B, Ragnarsson-Olding B, Sjovall K. Is there place for radiotherapy in the treatment of advanced ovarian cancer?. Radiother Oncol 1999, 53:213-218. 10.1016/S0167-8140(99)00144-9, 10660201.
20. Einhorn N, Trope C, Ridderheim M, Boman K, Sorbe B, Cavallin-Stahl E. A systematic overview of radiation therapy effects in ovarian cancer. Acta Oncol 2003, 42:562-566. 10.1080/02841860310014426, 14596514.
21. Fyles AW, Thomas GM, Pintilie M, Ackerman I, Levin W. A randomized study of two doses of abdominopelvic radiation therapy for patients with optimally debulked Stage I, II, and III ovarian cancer. Int J Radiat Oncol Biol Phys 1998, 41:543-549. 10.1016/S0360-3016(98)00066-2, 9635700.
22. Dinniwell R, Lock M, Pintilie M, Fyles A, Laframboise S, Depetrillo D, et al. Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer. Int J Radiat Oncol Biol Phys 2005, 62:104-110. 10.1016/j.ijrobp.2004.09.010, 15850909.
23. Whelan TJ, Dembo AJ, Bush RS, Sturgeon JF, Fine S, Pringle JF, et al. Complications of whole abdominal and pelvic radiotherapy following chemotherapy for advanced ovarian cancer. Int J Radiat Oncol Biol Phys 1992, 22:853-858. 10.1016/0360-3016(92)90779-H, 1555976.
24. Fuller DB, Sause WT, Plenk HP, Menlove RL. Analysis of postoperative radiation therapy in stage I through III epithelial ovarian carcinoma. J Clin Oncol 1987, 5:897-905.
25. Duthoy W, De Gersem W, Vergote K, Coghe M, Boterberg T, De Deene Y, et al. Whole abdominopelvic radiotherapy (WAPRT) using intensity-modulated arc therapy (IMAT): first clinical experience. Int J Radiat Oncol Biol Phys 2003, 57:1019-1032. 10.1016/S0360-3016(03)00663-1, 14575833.
26. Rochet N, Sterzing F, Jensen A, Dinkel J, Herfarth K, Schubert K, et al. Helical tomotherapy as a new treatment technique for whole abdominal irradiation. Strahlenther Onkol 2008, 184:145-149. 10.1007/s00066-008-1772-z, 18330510.
27. Debus J, Zierhut D, Didinger B, Schlegel W, Wannenmacher M. Inverse planning and intensity-modulated radiotherapy in patients with prostate cancer. Front Radiat Ther Oncol 2002, 36:25-34. full_text, 11842752.
28. Hong L, Alektiar K, Chui C, LoSasso T, Hunt M, Spirou S, et al. IMRT of large fields: whole-abdomen irradiation. Int J Radiat Oncol Biol Phys 2002, 54:278-289. 10.1016/S0360-3016(02)03298-4, 12183002.
29. Mackie TR, Holmes T, Swerdloff S, Reckwerdt P, Deasy JO, Yang J, et al. Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy. Med Phys 1993, 20:1709-1719. 10.1118/1.596958, 8309444.
30. Rochet N, Jensen AD, Sterzing F, Munter MW, Eichbaum MH, Schneeweiss A, et al. Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocol. BMC Cancer 2007, 7:227. 10.1186/1471-2407-7-227, 2212657, 18093313.
31. Rochet N, Sterzing F, Jensen AD, Dinkel J, Herfarth KK, Schubert K, et al. Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study. Int J Radiat Oncol Biol Phys 2010, 76:1382-1389. 10.1016/j.ijrobp.2009.03.061, 19628341.
32. Firat S, Murray K, Erickson B. High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes. Int J Radiat Oncol Biol Phys 2003, 57:201-207. 10.1016/S0360-3016(03)00510-8, 12909234.
33. Fyles AW, Dembo AJ, Bush RS, Levin W, Manchul LA, Pringle JF, et al. Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma. Int J Radiat Oncol Biol Phys 1992, 22:847-851. 10.1016/0360-3016(92)90778-G, 1555975.
34. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10. 10.1016/0197-2456(89)90015-9, 2702835.
35. Englert S, Kieser M. Adaptive designs for single-arm, phase II trials in oncology, Internal Report. 2010,